Chimerix Inc (CMRX) was Reiterated by FBR Capital to “Mkt Perform” while Lowering the Price Target of the company shares to $ 8 from a previous price target of $9 . FBR Capital advised their investors in a research report released on Aug 9, 2016.
Chimerix Inc opened for trading at $4.3 and hit $4.55 on the upside on Monday, eventually ending the session at $4.27, with a gain of 1.43% or 0.06 points. The heightened volatility saw the trading volume jump to 7,96,345 shares. Company has a market cap of $197 M.
In a different news, on Jun 28, 2016, Ernest Mario (director) purchased 50,000 shares at $3.70 per share price. According to the SEC, on Jun 28, 2016, M Michelle Berrey (CEO) purchased 13,188 shares at $3.69 per share price. On Mar 2, 2016, Timothy Wollaeger (director) purchased 10,000 shares at $4.61 per share price, according to the Form-4 filing with the securities and exchange commission.
Chimerix Inc. a biopharmaceutical company dedicated to discovering developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound brincidofovir (BCV CMX001) which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient orally administered dosing regimens. In addition it has an active discovery program focusing on viral targets. CMX157 is its second clinical-stage nucleotide analog uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug tenofovir. Tenofovir marketed under the brand name Viread and in multiple fixed-dose combinations is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered developed and selected a clinical candidate CMX669 for BK virus and cytomegalovirus (CMV).